The Medicines Company (NASDAQ:MDCO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 21, 2018, the Board of Directors of The Medicines Company (the “Company”) appointed Christopher Visioli the Chief Financial Officer and Treasurer of the Company, effective immediately. Mr. Visioli replaced William B. O’Connor, who is retiring from the Company. Mr. O’Connor ceased serving as the Company’s Chief Financial Officer on March 21, 2018, but will remain with the Company as a special advisor to the Chief Executive Officer through 2018 and will be primarily focused on the close-out of the Company’s non-core businesses and products.
Mr. Visioli, age 42, previously served as Senior Vice President, Financial Strategy for the Company from January 2015 to March 2018 and Vice President, Cardiovascular Care from January 2013 to December 2014. Mr. Visioli joined the Company in June 2003 and has worked in a variety of leadership roles in the organization, including finance, business development, investor relations, strategy, planning, and business leadership of the Cardiovascular Care unit. He has led many efforts in the organization to acquire products and establish partnerships in addition to leading long-term strategy and financial planning work. Prior to joining the Company and before going to business school, Mr. Visioli was a management consultant for Ernst & Young. Mr. Visioli holds a BS in electrical engineering from Cornell University and an MBA from Columbia Business School.
There are no transactions involving Mr. Visioli that would be required to be reported under Item 404(a) of Regulation S-K.
About The Medicines Company (NASDAQ:MDCO)
The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company’s products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.
